A multicenter study on early prediction of antipsychotic response in patients with schizophrenia

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2009
INTERVENTION: olanzapine/risperidone risperidone/olanzapine CONDITION: schizophrenia PRIMARY OUTCOME: The rate of remission at 4 weeks after the beginning of antipsychotics SECONDARY OUTCOME: the Positive and Negative Syndrome Scale (PANSS) ,Clinical Global Impression Change rating scale,Global Assessment of Functioning,the Drug‐induced Extrapyramidal Symptom Scale ,blood sugar, total cholesterol, triglyceride INCLUSION CRITERIA: schizophrenia, schizophreniform disorder, schizoaffective disorder (DSM‐IV: 295.xx)
Epistemonikos ID: bc43921f3dd1aace1abfc6769d5e4ffe19c08586
First added on: Aug 22, 2024